Use of REGEN-COV in Pediatric Patients After Heart Transplantation for Treatment and Post-Exposure Prophylaxis of COVID-19

PURPOSE: Pediatric heart transplant (HT) patients are vulnerable to severe COVID-19 disease. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2; comprising of Casirivimab and Indevimab. It recently received emergency use authorization by the U.S. FDA for use as p...

Descripción completa

Detalles Bibliográficos
Autores principales: Clifford, S.A., Rackley, J.S., Kimbro, A.K., Martin, E.S., Shih, R.S., Pietra, B.A., Fricker, F.J., Gupta, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
(1240)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988622/
http://dx.doi.org/10.1016/j.healun.2022.01.1261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988622/
http://dx.doi.org/10.1016/j.healun.2022.01.1261

Ejemplares similares